Management of Severe Abemaciclib-induced Liver Dysfunction: Feasibility of Switching to Palbociclib
In Vivo · 2026
DOI: 10.21873/invivo.14217 ↗Kurz gefasst
Fallbericht in der Zeitschrift In Vivo, 2026. Verfasst von Shinya Takada und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, National Hospital Organization Hokkaido Cancer Center, Sapporo, Japan; snowman198019@gmail.com. Hauptthemen laut MEDLINE: Benzimidazoles, Aminopyridines, Piperazines, Pyridines. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacy, National Hospital Organization Hokkaido Cancer Center, Sapporo, Japan; snowman198019@gmail.com.
- Department of Pharmacy, National Hospital Organization Hokkaido Cancer Center, Sapporo, Japan.
- Department of Breast Surgery, National Hospital Organization Hokkaido Cancer Center, Sapporo, Japan.
Zitieren
APA
Takada, S., Umehara, K., & Watanabe, K. (2026). Management of Severe Abemaciclib-induced Liver Dysfunction: Feasibility of Switching to Palbociclib. In Vivo. https://doi.org/10.21873/invivo.14217
Vancouver
Takada S, Umehara K, Watanabe K. Management of Severe Abemaciclib-induced Liver Dysfunction: Feasibility of Switching to Palbociclib. In Vivo. 2026. doi:10.21873/invivo.14217
BibTeX
@article{Takada2026,
author = {Takada, Shinya and Umehara, Kengo and Watanabe, Kenichi},
title = {Management of Severe Abemaciclib-induced Liver Dysfunction: Feasibility of Switching to Palbociclib},
journal = {In Vivo},
year = {2026},
doi = {10.21873/invivo.14217}
}
EUVIMED